Short-term and long-term prognostic value of circulating soluble suppression of tumorigenicity-2 concentration in acute coronary syndrome: a meta-analysis

Linlin Gu and Jing Li
Department of Emergency Intensive Care Unit, Affiliated Hospital of Jining Medical College, Jining 272200, China
Correspondence: Jing Li (jingli9921@yeah.net)

Background: Higher circulating soluble suppression of tumorigenicity-2 (sST2) concentration is suggested as a marker of prognosis in many cardiovascular diseases. However, the short-term and long-term prognostic value of sST2 concentration in acute coronary syndrome (ACS) remains to be summarized.

Methods: A meta-analysis of follow-up studies was performed. Studies were identified via systematic search of databases including PubMed, Cochrane’s Library, and Embase. A fixed- or random-effect model was applied according to the heterogeneity. We reported the prognostic value of sST2 concentration for all-cause mortality, heart failure (HF) events, and major adverse cardiovascular events (MACEs) within 1 month after hospitalization and during subsequent follow-up.

Results: Twelve studies with 11690 ACS patients were included. Higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (risk ratio [RR]: 3.16, \( P = 0.002 \)), HF events (RR: 1.48, \( P < 0.001 \)), and MACEs (RR: 1.47, \( P < 0.001 \)) within 1 month after hospitalization, which is consistent with the results with sST2 concentration as categorized variables (RR = 2.14, 2.89, and 2.89 respectively, \( P \) all < 0.001). Moreover, higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (RR: 2.20, \( P < 0.001 \)), HF events (RR: 1.39, \( P < 0.001 \)), and MACEs (RR: 1.53, \( P = 0.02 \)) during subsequent follow-up. Meta-analysis with sST2 concentration as categorized variables retrieved similar results (RR = 2.65, 2.59, and 1.81 respectively, \( P \) all < 0.001).

Conclusions: Higher circulating sST2 concentration at baseline predicts poor clinical outcome in ACS patients.

Introduction
With the aging of the global population, the prevalence of coronary artery disease (CAD) is increasing. Acute coronary syndrome (ACS), including ST segment elevated myocardial infarction (STEMI) and non-ST segment elevated ACS (NSTEMI-ACS) has now become the leading cause of mortality in general population, particularly in the elderly [1,2]. It was reported that approximately 800000 people experienced ACS annually in the United States, and approximately 30% of them had STEMI [3,4]. Characterized by acute plaque rupture and thrombosis formation in the coronary arteries, patients with ACS usually have higher risk for the development of heart failure (HF) and death [4–6]. Biomarkers such as cardiac troponin and B-type natriuretic peptide (BNP) play important roles for risk estimation in ACS patients [7,8]. Besides, recent studies indicate that other biomarkers such as soluble suppression of tumorigenicity-2.
(sST2) concentration also confer prognostic value in patients with ACS [9,10]. Pathophysiologically, interleukin 33 (IL-33) mediates various potential cardioprotective effect via interaction with transmembrane ST2 (ST2L), including anti-inflammation, anti-remodeling, and hypertrophy, and anti-apoptosis. Therefore, the sST2 has been demonstrated to attenuate the potential cardioprotective effect of IL-33/ST2L via acting as a decoy receptor [11]. Accordingly, previous meta-analyses showed that higher circulating sST2 concentration is associated with worse clinical outcomes in patients with acute and chronic HF [12,13]. For patients with ACS, although most of the pilot follow-up studies suggested that higher sST2 concentration at baseline predicts increased mortality risk [14–25], these studies vary in scales and follow-up durations, and quantitative analyses for the prognostic efficacy of sST2 concentration at baseline for short-term and long-term outcomes in ACS patients have not been performed. Therefore, the aim of the meta-analysis was to summarize the potential prognostic efficacy of sST2 concentration for short-term and long-term outcomes in ACS patients.

## Methods
### Database search
We performed this meta-analysis as instructed by the MOOSE (Meta-analysis of Observational Studies in Epidemiology) [26] and Cochrane's Handbook [27] guidelines. Databases of PubMed, Cochrane's Library, and Embase were searched for potential studies with the combined search terms of ‘suppression of tumorigenecity–2’, ‘suppression of tumorigenicity–2’ , ST2, sST2), and ‘myocardial infarction’, ‘acute coronary syndrome’, ‘ACS’, ‘unstable angina’, STEMI, or NSTEMI, on 29 October 2018. The search was limited to studies in humans that were published in English. The references of the related original papers and review articles were manually searched for additional potential studies.

### Inclusion and exclusion criteria
Studies fulfilling the following criteria were included: (i) follow-up studies, including post-hoc analysis of randomized controlled trials; (ii) included patients with ACS; (iii) sST2 concentration was measured at baseline; (iv) reported the adjusted risk ratios (RRs) and their corresponding 95% confidence intervals (CIs) for the incidences of all-cause mortality, HF events (HF incidence or hospitalization), and major adverse cardiovascular events (MACEs). Definition of MACEs was inconsistent with the original studies, including cardiovascular death, HF incidence or worsening, recurrent MI, and repeated target vessel revascularization (TVR). Reviews, meta-analysis, preclinical studies, and non-follow-up studies were excluded.

### Data extraction and quality evaluation
The following data were extracted: the study design, diagnosis of the patients, sample sizes, mean ages, proportions of males, methods for measuring sST2 concentration, follow-up durations, variables adjusted, and the statistical presentation of sST2 concentration (as continuous or categorized variables). The quality evaluation was performed with the Newcastle–Ottawa Scale [28] which ranges from 1 to 9 stars and evaluates the quality of each study based on three aspects: selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest. Two reviewers performed database search, data extraction, and quality evaluation independently.

### Statistical analyses
We used RRs as the general measure for the prognostic efficacy of sST2 concentration for ACS. For studies presenting sST2 concentration as continuous variables, log transformation of sST2 concentration was performed in the original studies because of the skewed distribution, and RRs for log (sST2) were extracted. For those sST2 concentration was presented as categorized variables, RRs for comparing patients from the highest and the lowest category of sST2 concentration were extracted. We calculated corresponding stand errors (SEs) or RRs from 95% CIs or P values, and logarithmically transformed them to stabilize the variance and normalize the distribution [27]. The Cochrane’s Q test and I² test were used to evaluate the heterogeneity among the include cohort studies [27,29]. A significant heterogeneity was considered if $I^2 > 50\%$. We used a random-effect model to synthesize the RR data if heterogeneity was significant; otherwise, a fixed-effect model was applied. We reported the prognostic value of sST2 concentration for each outcome both within 1 month after hospitalization and during subsequent follow-up. Potential publication bias was evaluated by funnel plots with the Egger regression asymmetry test [30]. The RevMan (Version 5.1; Cochrane Collaboration, Oxford, U.K.) and STATA software were applied for the statistics.
Results

Search, study inclusion, and characteristics

The flowchart of database search is presented in Figure 1. Of the 451 initially identified studies, 12 were finally included [14–25] and listed in Table 1. This meta-analysis included five post-hoc analysis [14–16,18,20] and seven prospective cohort studies [17,19,21–25] with 11690 ACS patients. Eight studies included STEMI patients [14,15,19,20,22–25], three studies included NSTE-ACS patients [16–18], and the other one included both [21]. Baseline circulating sST2 concentrations were measured with enzyme-linked immunosorbent assay (ELISA) methods from MBL, R&D, and Presage, while rapid test was applied in one study [23]. The follow-up varied from 1 month to 5 years. Various confounding factors such as age, gender, medical histories, comorbidities, biochemical parameters, and treatments were adjusted when presenting the RRs in the included studies. The NOS varied from 7 to 9 points, indicating generally good study qualities.

Short-term prognostic value of sST2 concentration in ACS

Pooled results with three to five studies showed that higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (RR: 3.16, 95% CI: 1.52–6.61, \(P = 0.002; I^2 = 92\%\); Figure 2A), HF events (RR: 1.48, 95% CI: 1.26–1.74, \(P < 0.001; I^2 = 0\%\); Figure 2B), and MACEs (RR: 1.47, 95% CI: 1.29–1.69, \(P < 0.001; I^2 = 0\%\); Figure 2C) within 1 month after hospitalization. These results were further confirmed by meta-analysis of studies.
Table 1 Characteristics of the included cohort studies

| Study         | Country | Design   | Diagnosis          | Sample size | Age | Male | sST2 measurement | Follow-up time | sST2 cutoff | Variables adjusted                                                                 | NOS |
|---------------|---------|----------|--------------------|-------------|-----|------|------------------|----------------|-------------|-------------------------------------------------------------------------------------|-----|
| Shimpo 2004 [14] | U.S.A.  | Post-hoc | STEMI              | 810          | 58  | 80   | MBL ELISA assay   | 1              | Continuous | Age, HR, SBP, infarct location, Killip class, time from symptom onset, and TIMI flow grade of IRA | 7   |
| Sabatine 2008 [15] | U.S.A.  | Post-hoc | STEMI              | 1239         | 58  | 78   | MBL ELISA assay   | 1              | Continuous and Q4/Q1 | Age, sex, hypertension, DM, prior MI, prior CHF, eGFR, infarct location, Killip class, time from symptom onset, and peak CK | 7   |
| Eggers 2010 [16] | Sweden | Post-hoc | NSTE-ACS           | 403          | 69  | 65   | Presage ST2 assay | 12             | Continuous | Age, CHF, DM, previous MI, and previous stroke                                      | 8   |
| Dhillon 2011 [17] | U.K.   | PC       | NSTEMI             | 577          | 70  | 69   | ELISA (R&D)       | 1 and 18       | Continuous and Q4/Q1-3 | Age, gender, smoking previous angina or AMI, HF, hypertension, DM, Killip class, eGFR, FBG, Tnl, use of BBs and statins | 8   |
| Kohli 2012 [18]  | U.S.A.  | Post-hoc | NSTE-ACS           | 4426         | NA  | 66   | Presage ST2 assay | 1 and 12       | Continuous and Q4/Q1-3 | Age, CAD, DM, hypertension, dyslipidemia, severe angina, ST changes, smoking, history of HF, eGFR, Tnl, BNP, hsCRP, and use of aspirin | 8   |
| Dhillon 2013 [19] | U.K.   | PC       | STEMI              | 677          | 64  | 75   | ELISA (R&D)       | 1 and 12       | Continuous and Q4/Q1-3 | Age, gender, previous history of angina/AMI, hypertension, DM, Killip Class, eGFR, peak CK, treatment with thrombolyis, BB, statins, ACEIs or ARBs | 9   |
| O’Donoghue 2016 [20] | U.S.A.  | Post-hoc | STEMI              | 1258         | 58  | 79   | MBL ELISA assay   | 1              | Q4/Q1-3               | Age, sex, past HF, DM, past MI, SBP, HR, Killip class, infarct location, eGFR, and time from symptom onset | 7   |
| Jenkins 2017 [21] | U.S.A.  | PC       | AMI (STEMI: 291, NSTEMI: 1110) | 1401       | 67  | 61   | Presage ST2 assay | 1, 12 and 60  | Continuous and T3/T1 | Age, sex, Charlson comorbidity index, Killip class, and maximum TnlT                | 9   |
| Yu 2017 [22]     | Korea   | PC       | STEMI              | 323          | 59  | 84   | ELISA (R&D)       | 12             | Median               | Age, DM, final TIMI flow grade, hypoxic liver injury, hs-CRP level, and Tnl level   | 8   |
| Huang 2018 [24]  | China   | PC       | STEMI              | 186          | 62  | 74   | Presage ST2 assay | 12             | Median               | Age, gender, smoking, SBP, HR, Killip Class, LVEF, eGFR, NT-proBNP, Tnl, CRP, and pPCI | 8   |
| Hartopo 2018 [23] | Indonesia | PC    | STEMI              | 95           | 58  | 76   | ASPECT PLUS Rapid ST2 Test | 12             | Median               | Age, DM, HR, Hb, SCr, FBG, Tg, Tnl, and infarct location                          | 8   |
| Liu 2018 [25]    | China   | PC       | STEMI              | 295          | 60  | 83   | Presage ST2 assay | 12             | Q4/Q1                | Age, gender, smoking, SBP, HR, Killip Class, LVEF, eGFR, infarct location, time from onset to ER, NT-proBNP, Tnl, CRP, and IL-6 | 8   |

Abbreviations: ACEI, angiotensin converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin II receptor blocker; BB, β blocker; CHF, congestive HF; CK, creatine kinase; DM, diabetes mellitus; eGFR, estimated glomerular filtrating rate; ER, emergency room; FBG, fasting blood glucose; Hb, hemoglobin; HR, heart rate; hs-CRP, high-sensitive C-reactive protein; IL-6, interleukin 6; IRA, infarct related artery; LVEF, left ventricular ejection fraction; MBL, Medical & Biological Laboratories; MI, myocardial infarction; NOS, Newcastle–Ottawa Scale; PC, prospective cohort; NT-proBNP, N-terminal pro BNP; pPCI, primary percutaneous coronary intervention; Q, quartile; SBP, systolic blood pressure; T, tertile; TG, TIMI, Thrombolysis in Myocardial Infarction; triglyceride; Tnl, troponin I; TnT, troponin T.
Figure 2. Forest plots for the meta-analysis of short-term prognostic value of sST2 concentration in ACS patients with sST2 concentration presented as continuous variable
(A) All-cause mortality; (B) HF events; (C) MACEs.

Figure 3. Forest plots for the meta-analysis of short-term prognostic value of sST2 concentration in ACS patients with sST2 concentration presented as categorized variable
(A) All-cause mortality; (B) HF events; (C) MACEs.

with sST2 concentration presented as categorized variables. Compared with patients with baseline sST2 concentration in the lowest categories, those in the highest categories had significantly higher incidences of short-term all-cause mortality (RR: 2.14, 95% CI: 1.44–3.19, \( P < 0.001; I^2 = 0\%\); Figure 3A), HF events (RR: 2.89, 95% CI: 2.00–4.18,
Figure 4. Forest plots for the meta-analysis of long-term prognostic value of sST2 concentration in ACS patients with sST2 concentration presented as continuous variable

(A) All-cause mortality; (B) HF events; (C) MACEs.

Long-term prognostic value of sST2 concentration in ACS

Pooled results with two to six studies showed that higher baseline sST2 concentration as continuous variables predict the increased risk of all-cause mortality (RR: 2.20, 95% CI: 1.46–3.33, \( P < 0.001; I^2 = 88\%\); Figure 4A), HF events (RR: 1.39, 95% CI: 1.23–1.57, \( P < 0.001; I^2 = 0\%\); Figure 4B), and MACEs (RR: 1.53, 95% CI: 1.07–2.20, \( P = 0.02; I^2 = 59\%\); Figure 4C) during subsequent follow-up to 5 years after hospitalization. These were further confirmed by meta-analysis with sST2 concentration as categorized variables (all-cause mortality: RR: 2.65, 95% CI: 1.25–5.61, \( P < 0.001; I^2 = 88\%\); Figure 5A; HF events: RR: 2.59, 95% CI: 2.06–3.25, \( P < 0.001; I^2 = 0\%\); Figure 5B; and MACEs: RR: 1.81, 95% CI: 1.47–2.23, \( P < 0.001; I^2 = 0\%\); Figure 5C). The publication biases of the meta-analyses could not be estimated due to the limited number of included studies.

Sensitivity analyses

In view of the fact that the patients included in the study by Kohli et al. [18] accounted for 37.86% of the whole patients of the whole meta-analysis, sensitive analyses by omitting this study were performed. The results were not changed for most of the outcomes after omitting the study by Kohli et al. [18] except that the prognostic efficacy of sST2 concentration as continuous variable for short-term HF events becomes insignificant (RR: 1.79, 95% CI: 0.74–4.36, \( P = 0.20\); Table 2).

Discussion

Current risk stratification for patients with STEMI and NSTE-ACS mainly depends on the application of risk stratification systems including TIMI (Thrombolysis in Myocardial Infarction) [31] and GRACE (Global Registry of Acute Cardiac Events) [32] risk scores. As these systems have been proved to confer satisfying efficacies for risk stratification and recommended by current guidelines for ACS, it has been decades since the validation of the risk scores, and changes of the disease profiles and treatment patterns may require adding new factors to optimize the prognostic efficacies of these tools. Novel cardiac biomarkers such as sST2 may be one of them [9]. In this study, based on the
Figure 5. Forest plots for the meta-analysis of long-term prognostic value of sST2 concentration in ACS patients with sST2 concentration presented as categorized variable
(A) All-cause mortality; (B) HF events; (C) MACEs.

Table 2 Sensitivity analyses by omitting the study by Kohli et al. [18]

| Outcomes                     | Number of studies | RR (95% CI)      | P-values |
|------------------------------|-------------------|------------------|----------|
| Short-term                   |                   |                  |          |
| All-cause mortality (continuous) | 4                 | 3.99 [1.99, 8.02] | <0.001   |
| HF events (continuous)       | 2                 | 1.79 [0.74, 4.36] | 0.20     |
| MACEs (continuous)           | 2                 | 1.91 [1.24, 2.92] | 0.003    |
| All-cause mortality (categories) | 1                | 2.63 [1.36, 5.09] | 0.004    |
| HF events (categories)       | 1                 | 2.68 [1.35, 5.34] | 0.005    |
| MACEs events (categories)    | 2                 | 3.70 [1.99, 6.26] | <0.001   |
| Long-term                    |                   |                  |          |
| All-cause mortality (continuous) | 5                | 2.49 [2.08, 2.99] | <0.001   |
| HF events (continuous)       | 2                 | 1.86 [1.05, 3.31] | 0.03     |
| MACEs events (continuous)    | 1                 | 2.01 [1.24, 3.27] | 0.005    |
| All-cause mortality (categories) | 2                | 3.64 [2.64, 5.01] | <0.001   |
| HF events (categories)       | 1                 | 2.88 [2.05, 4.05] | <0.001   |
| MACEs events (categories)    | 4                 | 2.49 [1.57, 3.93] | <0.001   |

meta-analysis of multivariable adjusted follow-up studies, demonstrated that baseline level of sST2 concentration is an important prognostic factor for the clinical outcomes in ACS, including all-cause mortality, HF events, and MACEs. The independent association between circulating sST2 concentration and poor clinical outcomes in ACS was observed after the full adjustment of potential confounding factors in our meta-analysis, which was independent of the follow-up durations and patterns of sST2 concentration presentation in statistical analyses. Our results, therefore, it can be estimated that including circulating sST2 concentration into the above ACS risk scores may improve their overall predictive efficacy. In fact, a recent study including MI patients showed that incorporation of sST2 concentration into the GRACE and TIMI risk scores significantly improved the discriminatory performances of the systems [33]. Moreover, as a cardiac biomarker, sST2 concentration in circulation is found to be stable and unlikely to be affected by age, body mass index, or renal function [34–37]. These findings support that incorporation of measuring sST2 concentration is rationale for risk stratification and clinical decision making for ACS patients.
Physiologically, sST2 is a circulating isoform of ST2, which may antagonize the effect of IL-33 mediated by the ST2L by functioning as a decoy receptor \[11,38\]. Enhanced release of sST2 in peripheral circulating during acute myocardial ischemia further attenuates the cardioprotective effects of the IL-33/ST2L system, which finally contributes to the vulnerability of the patients to cardiac dysfunction and related adverse clinical outcomes \[38\]. These may be the molecular basis for the prognostic role of sST2 concentration in ACS patients.

Our study has strengths such as including fully adjusted results of the studies, with analyses of both the short-term and long-term prognostic efficacies of sST2 concentrations, and with analyses of sST2 concentrations presented in different variable patterns. However, our study also has limitations, which should be noticed when interpreting the results. First, the number of the included studies in each stratum of the meta-analysis is relatively small, which prevented us from analyzing the sources of heterogeneities that was detected for some outcomes. Second, we did not have individual patient data of the included follow-up studies. Based on the data of study-level, we were unable to determine whether the prognostic value of sST2 concentration differs in patients with STEMI and NSTE-ACS, in the male and the female, and in those with and without cardiac dysfunction. Future studies with large sample sizes are needed to answer these questions. Moreover, as a meta-analysis of observational studies, we could not exclude the chance that some residual factors may confound the association between sST2 concentration and poor prognosis in ACS patients. In addition, the study by Kohli et al. \[18\] had much larger sample size than others, and for some outcomes, the results seem to be mainly driven by this study, which may lead to bias. However, sensitive analyses by omitting this study retrieved similar results. Finally, different measurement methods for sST2 concentration were applied in the included studies, of which, the Presage assay has been proved to be of better precision than others \[36,39\]. These may also lead to the heterogeneity of the meta-analysis.

In conclusion, higher sST2 concentration at baseline predicts poor clinical outcome in ACS patients. Current findings support the incorporation of measuring circulating sST2 concentration in clinical practice for risk stratification and decision making in ACS patients.

**Competing Interests**
The authors declare that there are no competing interests associated with the manuscript.

**Author Contribution**
J.L. designed the study. Both authors collected the data, performed statistical analyses and interpreted the results. L.G. drafted the manuscript and J.L. critically reviewed the manuscript.

**Funding**
The authors declare that there are no sources of funding to be acknowledged.

**Abbreviations**
ACS, acute coronary syndrome; BNP, B-type natriuretic peptide; CI, confidence interval; GRACE, Global Registry of Acute Cardiac Events; HF, heart failure; IL-33, interleukin 33; MACE, major adverse cardiovascular event; NSTE-ACS, non-ST segment elevated ACS; RR, risk ratio; sST2, soluble suppression of tumorigenicity-2; STEMI, ST segment elevated myocardial infarction; ST2L, transmembrane isoform of ST2; TIMI, thrombolysis in myocardial infarction.

**References**

1. Chan, M.Y., Du, X., Eccleston, D. et al. (2016) Acute coronary syndrome in the Asia-Pacific region. *Int. J. Cardiol.* 202, 861–869, https://doi.org/10.1016/j.ijcard.2015.04.073
2. Shechter, M., Rubinstein, R., Goldenberg, I. and Matezki, S. (2017) Comparison of outcomes of acute coronary syndrome in patients ≥80 years versus those <80 years in Israel from 2000 to 2013. *Am. J. Cardiol.* 120, 1230–1237
3. Benjamin, E.J., Virani, S.S., Callaway, C.W. et al. (2018) Heart Disease and Stroke Statistics-2018 Update: a report from the American Heart Association. *Circulation* 137, e67–e492. https://doi.org/10.1161/CIR.0000000000000558
4. O’Gara, P.T., Kushner, F.G., Ascheim, D.D. et al. (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J. Am. Coll. Cardiol.* 61, e78–e140, https://doi.org/10.1016/j.jacc.2012.11.019
5. Hao, Y., Liu, J., Smith, Jr, S.C. et al. (2016) Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: a national effort to prompt quality enhancement for acute coronary syndrome. *Am. Heart J.* 179, 107–115, https://doi.org/10.1016/j.ahj.2016.06.005
6. Roffi, M., Patrono, C., Collet, J.P. et al. (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur. Heart J.* 37, 267–315, https://doi.org/10.1093/eurheartj/ehv320
7 Garg, P., Morris, P., Faztanie, A.L. et al. (2017) Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern. Emerg. Med. 12, 147–155, https://doi.org/10.1007/s11739-017-1612-1
8 Saenger, A.K. and Korpü-Steiner, N. (2017) Advances in cardiac biomarkers of acute coronary syndrome. Adv. Clin. Chem. 78, 1–58, https://doi.org/10.1016/bs.acc.2016.07.001
9 Salvagno, G.L. and Pavan, C. (2016) Prognostic biomarkers in acute coronary syndrome. Ann. Transl. Med. 4, 258, https://doi.org/10.21037/atm.2016.06.36
10 Cao, R.Y., Zheng, H., Guo, J. and Redfearn, D.P. (2016) Prognostic value of plasma biomarkers in patients with acute coronary syndrome: a review of advances in the past decade. Biomark. Med. 10, 525–535, https://doi.org/10.2217/bmm-2015-0029
11 Altara, R., Ghali, R., Maltat, Z., Catalotti, A., Booz, G.W. and Zwein, F.A. (2018) Conflicting vascular and metabolic impact of the IL-33/sST2 axis. Cardiovasc. Res. 114, 1578–1594, https://doi.org/10.1093/cvr/cvy166
12 Almo, A., Vergaro, G., Passino, C. et al. (2017) Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail. 5, 280–286, https://doi.org/10.1016/j.jchf.2016.12.016
13 Aimo, A., Vergaro, G., Ripoli, A. et al. (2017) Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure. JACC Heart Fail. 5, 287–296, https://doi.org/10.1016/j.jchf.2016.12.016
14 Shimplo, M., Morrow, D.A., Weinberg, E.O. et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 109, 2186–2190, https://doi.org/10.1161/01.CIR.0000127958.21003.5A
15 Sabatine, M.S., Morrow, D.A., Higgins, L.J. et al. (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117, 1936–1944, https://doi.org/10.1161/CIRCULATIONAHA.107.728022
16 Eggers, K.M., Armstrong, P.W., Calif, R.M. et al. (2010) ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am. Heart J. 159, 788–794, https://doi.org/10.1016/j.ahj.2010.02.022
17 Dhillon, O.S., Narayan, H.K., Quinn, P.A., Squire, I.B., Davies, J.E. and Ng, L.L. (2011) Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. J. Am. Heart J. 161, 1163–1170, https://doi.org/10.1016/j.amjheart.2011.03.025
18 Kohli, P., Bonaca, M.P., Kakkar, R. et al. (2012) Role of ST2 in non-ST-segment elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin. Chem. 58, 257–266, https://doi.org/10.1373/clinchem.2011.173369
19 Dhillon, O.S., Narayan, H.K., Khan, S.O. et al. (2013) Pre-discharge risk stratification in unselectedSTEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int. J. Cardiol. 167, 2182–2188, https://doi.org/10.1016/j.ijicard.2012.05.073
20 O’Donoghue, M.L., Morrow, D.A., Cannon, C.P., Jarolim, P., Desai, N.R., Sherwood, M.W. et al. (2016) Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. Journal of the american heart association 5, e002586, https://doi.org/10.1161/JAHA.115.002586
21 Jenkins, W.S., Roger, V.L., Jaffe, A.S. et al. (2017) Prognostic value of soluble ST2 after myocardial infarction: a community perspective. Am. J. Med. 130, 1112.e9–e15, https://doi.org/10.1016/j.amjmed.2017.02.034
22 Yu, J., Oh, P.C., Kim, M. et al. (2017) Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP. PLoS ONE 12, e0182629, https://doi.org/10.1371/journal.pone.0182629
23 Hartopo, A.B., Sukmasari, I. and Puspitawati, I. (2018) The utility of point of care test for soluble ST2 in predicting adverse cardiac events during acute care of ST-segment elevation myocardial infarction. Cardioi. Res. Pract. 18, 3048941
24 Huang, W., Zheng, X., He, L., Su, X., Liu, C.W. and Wu, M.X. (2018) Role of soluble ST2 levels and beta-blockers dosage on cardiovascular events of patients with unselected ST-segment elevation myocardial infarction. Chin. Med. J. 131, 1282–1288, https://doi.org/10.4103/0386-6999.232181
25 Liu, X., Hu, Y., Huang, W. et al. (2018) Soluble ST2 for prediction of clinical outcomes in patients with ST-segment elevation myocardial infarction receiving primary PCI. Int. Heart J. 60, 19–26, https://doi.org/10.1530/ihj.18.020
26 Stroup, D.F., Berlin, J.A., Morton, S.C. et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012, https://doi.org/10.1001/jama.2001.1083.152008
27 Higgins, J. and Green, S. (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration, www.cochranehandbook.org
28 Wells, G.A., Shea, B., O’Connell, D. et al. (2010) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
29 Higgins, J.P. and Thompson, S.G. (2002) Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558, https://doi.org/10.1002/sim.1186
30 Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634, https://doi.org/10.1136/bmj.315.7109.629
31 Antman, E.M., Cohen, M., Bernink, P.J. et al. (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284, 835–842, https://doi.org/10.1001/jama.284.7.835
32 Granger, C.B., Goldberg, R.J., Dabbous, O. et al. (2003) Predictors of hospital mortality in the global registry of acute coronary events. Arch. Intern. Med. 163, 2345–2353, https://doi.org/10.1001/archinte.163.19.2345
33 Gerber, Y., Weston, S.A., Enríquez-Sarano, M. et al. (2017) Contemporary risk stratification after myocardial infarction in the community: performance of scores and incremental value of soluble suppression of tumorigenicity-2. J. Am. Heart. Assoc. 6, e005958, https://doi.org/10.1161/JAHA.1005958
34 Ho, J.E., Sritara, P., deFilippi, C.R. and Wang, T.J. (2015) Soluble ST2 testing in the general population. Am. J. Cardiol. 115, 228–258, https://doi.org/10.1016/j.amijcard.2015.01.038
35 Mueller, T. and Jaffe, A.S. (2015) Soluble ST2—analytical considerations. Am. J. Cardiol. 115, 88–218, https://doi.org/10.1016/j.amijcard.2015.01.035
36 Mueller, T. and Dieplinger, B. (2013) The Presage(R) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. *Expert Rev. Mol. Diagn.* **13**, 13–30, [https://doi.org/10.1586/erm.12.128](https://doi.org/10.1586/erm.12.128)

37 Wu, A.H., Wians, F. and Jaffe, A. (2013) Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. *Am. Heart J.* **165**, 995–999, [https://doi.org/10.1016/j.ahj.2013.02.029](https://doi.org/10.1016/j.ahj.2013.02.029)

38 Pascual-Figal, D.A. and Januzzi, J.L. (2015) The biology of ST2: the International ST2 Consensus Panel. *Am. J. Cardiol.* **115**, 3B–7B, [https://doi.org/10.1016/j.amjcard.2015.01.034](https://doi.org/10.1016/j.amjcard.2015.01.034)

39 Mueller, T., Zimmermann, M., Dieplinger, B., Ankersmit, H.J. and Haltmayer, M. (2012) Comparison of plasma concentrations of soluble ST2 measured by three different commercially available assays: the MBL ST2 assay, the Presage ST2 assay, and the R&D ST2 assay. *Clin. Chim. Acta* **413**, 1493–1494